VANCOUVER, BC, May 14, 2024 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2024. "This quarter we have continued to advance Filament's drug development efforts in substance use disorders, as evidenced by the opening of our first IND with FDA in the United States. " said Benjamin Lightburn, Chief Executive Officer and Co-Founder at Filament Health. "We expanded our network of licensing partners to new jurisdictions around the globe and our botanical psilocybin drug candidate, PEX010, is now authorized for investigation in 31 clinical trials worldwide for 13 mental health indications.." Q1 2024 Financial Highlights: Cash and cash equivalents of $872,048 and a working capital of $359,664 as of March ...